Beverages 7
Jingye Zhou, Eccogene CEO Eccogene files for Hong Kong IPO to back development of GLP-1 pipeline Eccogene, a clinical-stage biotech whose oral GLP-1 drug forms the backbone of AstraZenecas obesity pipeline, is planning an initial public offering on the Hong Kong Sign up to read this article for free
Mounjaro GLP-1 Weight Loss Tracker Track your Mounjaro (tirzepatide) injections, monitor side effects and visualize estimated medication levels across your GLP-1 cycle
The shortage-based legal exemption that underpinned widespread compounded semaglutide availability is no longer active for either 503A pharmacies or 503B outsourcing facilities Compounded GLP-1 programs operating today must navigate a legal framework that includes restrictions on compounding drugs that are commercially available drugs - meaning the compounding pharmacy's specific formulation, documentation, and prescriber individualization process matters for legal compliance The FDA still permits compounding under 503A for individual patient-specific prescriptions that involve a prescriber-documented "significant difference" from the commercially available product - but that requires specific clinical justification, not just a standard intake form Availability of specific compounded GLP-1 formulations may be affected by FDA enforcement actions, pharmacy-specific compliance status, and ongoing regulatory developments in this space None of this means compounded GLP-1 programs are operating illegally
Doctors want patients who will use medications correctly, and these questions signal that commitment
